Stockreport

BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ... [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF Research and Development Expenses: EUR550 million for Q3 2024, up from EUR498 million in Q3 2023. Sales, General and Administrative Expenses: EUR151 million for Q3 20 [Read more]